ZVRA MEXC RealStocks
Own real ZVRA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 17:16:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Zevra Therapeutics, Inc. (ZVRA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $11.39, with a market capitalization of $709.30M and a P/E ratio of 9.17. Over the past 52 weeks, its price has ranged from $8.01 to $15.04. This page covers its latest market performance, valuation, price trends and company information.
$709.30M | |
$11.75 | |
$12.16 | |
$11.26 | |
$11.85 | |
277.26K | |
912.78K | |
9.17 | |
$15.04 | |
$8.01 | |
-- | |
-- |
Zevra Therapeutics, Inc. (ZVRA) is currently trading at $11.39 as of 2026-11-12 17:15:00, down 3.50% ($0.41) from the previous close of $11.85
During today's regular trading session, ZVRA has traded between $11.26 and $12.16, with a trading volume of 277.26K shares. The current price is near the lower end of today's range.
Over the past seven days, Zevra Therapeutics, Inc. (ZVRA) moved from $10.26 to $11.39, representing a gain of 11.05% ($1.13).
The stock traded between $10.04 and $12.20 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.38 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 48.2%
ZVRA is currently trading at $11.39, placing it 48.2% of the way from its 52-week low of $8.01 to its 52-week high of $15.04. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 61 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Zevra Therapeutics, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Zevra Therapeutics, Inc. (ZVRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ZVRA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ZVRA shares and USD.
ZVRA Shares to USD
1.00 ZVRA shares = 11.394 USD
Calculations are estimates based on the latest available price and are for reference only.